Schrödinger Inc. (SDGR)
undefined
undefined%
At close: undefined
20.83
0.12%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications.

The company operates in two segments, Software and Drug Discovery.

The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.

The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.

The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide.

Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrödinger Inc.
Schrödinger Inc. logo
Country United States
IPO Date Feb 6, 2020
Industry Medical - Healthcare Information Services
Sector Healthcare
Employees 900
CEO Dr. Ramy Farid Ph.D.

Contact Details

Address:
1540 Broadway
New York, New York
United States
Website https://www.schrodinger.com

Stock Details

Ticker Symbol SDGR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001490978
CUSIP Number 80810D103
ISIN Number US80810D1037
Employer ID 95-4284541
SIC Code 2834

Key Executives

Name Position
Dr. Ramy Farid Ph.D. Chief Executive Officer, President & Director
Dr. Geoffrey Craig Porges MBBS Executive Vice President & Chief Financial Officer
Kenneth Patrick Lorton Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software
Shane Brauner Executive Vice President & Chief Information Officer
Dr. Karen Akinsanya Ph.D. President of Research & Development Therapeutics
Dr. Margaret Han Dugan M.D. Chief Medical Officer
Dr. Richard A. Friesner Ph.D. Co-Founder, Scientific Advisory Chairman and Director
Dr. Robert Lorne Abel Ph.D. Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D
Jaren Irene Madden Senior Vice President of Investor Relations & Corporate Affairs
Prof. William Goddard III Co-Founder & Scientific Advisor

Latest SEC Filings

Date Type Title
Nov 13, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 12, 2024 10-Q Quarterly Report
Oct 16, 2024 4 Filing
Sep 12, 2024 8-K Current Report
Jul 31, 2024 S-8 Filing
Jul 31, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jun 20, 2024 4 Filing
Jun 20, 2024 4 Filing
Jun 20, 2024 4 Filing